KROS

Business Context and Reporting Period

Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company developing therapeutics targeting the TGF-β family of proteins. The reporting period covers the fiscal year ended December 31, 2025. The company focuses on two primary product candidates: rinvatercept (KER-065) for neuromuscular diseases (Duchenne muscular dystrophy and ALS) and elritercept (KER-050) for cytopenias in myelodysplastic syndromes (MDS) and myelofibrosis.

Key Financial Metrics

Revenue Composition (2025): Revenue was driven by a $200.0 million upfront payment and a $10.0 million milestone payment from the Takeda license agreement, plus $38.5 million in transition service revenue. No product sales revenue was generated.

Material Changes vs. Prior Period

• Profitability Shift: The company reported a net income of $87.0 million in 2025, a reversal from a net loss of $187.4 million in 2024. This was primarily due to the recognition of $205.4 million in license revenue from the Takeda agreement.
• Expense Reduction: R&D expenses decreased by $44.0 million (25%) year-over-year. This reduction was driven by a 45% workforce reduction (restructuring) completed in July 2025, the termination of the cibotercept program, and the transition of elritercept clinical activities to Takeda.
• Cash Position: Cash and cash equivalents decreased by $272.5 million to $287.4 million. This decline was primarily due to $375.0 million in share repurchases (via tender offer and negotiated agreements) and operating cash outflows, partially offset by the Takeda upfront payment.
• Stock Repurchases: The company completed a $375.0 million capital return program in late 2025, repurchasing approximately 21.1 million shares of common stock.

Guidance, Outlook, and Risks

• Clinical Milestones:
  • Rinvatercept: Phase 1 in healthy volunteers completed with positive safety and pharmacodynamic data. Phase 2 in DMD patients is expected to commence in Q2 2026. Regulator engagement for ALS Phase 2 is planned for H2 2026.
  • Elritercept: The Phase 3 RENEW trial in lower-risk MDS patients initiated dosing in July 2025, triggering a $10 million milestone payment to Keros. Development and commercialization outside China are led by Takeda.
• Liquidity Outlook: Management expects existing cash resources ($287.4 million) to fund operations into the first half of 2028. The company does not expect to generate product revenue until regulatory approval is obtained.
• Restructuring: A 45% workforce reduction was implemented in May 2025 to reduce annualized costs by approximately $17 million. Total restructuring costs were $3.1 million.
• Key Risks:
  • Dependence on the success of rinvatercept and elritercept clinical trials.
  • Reliance on Takeda and Hansoh for the commercialization of elritercept; termination of these agreements could eliminate future revenue streams.
  • Need for additional capital if clinical development costs exceed current projections or if funding is required sooner than anticipated.
  • Regulatory risks, including the potential for clinical trial delays or failure to obtain marketing approval.

Investor Verification Checklist

• Takeda Agreement Terms: Verify the specific performance obligations and payment schedules for the remaining $80 million in development milestones and $1.02 billion in potential commercial/sales milestones.
• Cash Runway: Confirm the $287.4 million cash balance and the assumptions used to project funding sufficiency through H1 2028, particularly given the cessation of the ATM offering.
• Restructuring Impact: Assess whether the 45% headcount reduction has impacted the timeline for the planned Q2 2026 rinvatercept Phase 2 trial.
• Share Repurchase Impact: Review the dilution effects and remaining authorized share count following the $375 million buyback program.
• Elritercept Trial Progress: Monitor patient enrollment rates and interim data from the Phase 3 RENEW trial, as this is the primary catalyst for future value.